- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07938528
Strategy of Intracoronary Imaging Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels (STENTLESS II)
Strategies of Intracoronary Imaging Guided Drug-coated Balloons (DCB) Versus Angiography Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels Trial (STENTLESS II)
A number of 2570 patients scheduled for percutaneous coronary intervention (PCI) with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm) suitable for DCB implantation are openly randomized 1:1 to either intracoronary imaging guidance or angiographic guidance groups. The primary objective is to determine whether the IVUS/OCT-guided DCB strategy reduces the incidence of target vessel failure (TVF) at 12 months compared with the coronary angiography (CAG)-guided strategy.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This study is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of IVUS/OCT-guided drug-coated balloon (DCB) strategy compared with a CAG-guided strategy in patients with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm). Both groups will follow standardized angiographic safety criteria, with bailout drug-eluting stent (DES) implantation permitted when necessary. In the IVUS/OCT-guided group, lesion assessment, preparation, DCB treatment, and bailout stenting decisions will be optimized according to a predefined IVUS/OCT criterion, whereas the CAG-guided group will undergo treatment primarily based on angiographic assessment.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Erli Zhang
- Telefoonnummer: +86 18500853301
- E-mail: zhangerli@fuwaihospital.org
Studie Locaties
-
-
-
Beijing, China, 100037
- Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Participants must meet all of the following three criteria:
- Age ≥18 years;
- De novo lesions of large coronary vessels with the diameter of target lesion reference vessel ≥ 2.75 mm;
- One or more trial target vessel (LAD, LCX or RCA) is considered to require intervention and is suitable for treatment with DCB.
Exclusion Criteria:
Participants who meet any of the following conditions are not eligible for inclusion:
- Patients with hemodynamically unstable acute coronary syndrome
- Previous percutaneous coronary intervention (including stent implantation, plain old balloon angioplasty, and DCB angioplasty) on the target vessel within 12 months
- In-stent restenosis requiring revascularization
- Complex Coronary Bifurcation Lesions*
- Lesions with any of the following anatomical characteristics are presumably not suitable for DCB treatment:
1) Chronic total occlusion* 2) Left main coronary artery lesion and left main bifurcation lesion 3) Venous or arterial graft lesion 4) Moderated-Severe tortuous, or severe angulated vessels 6. cardiogenic shock 7. Concurrent medical condition with a life expectancy of less than 1 year. 8. Known contraindication to medications such as Aspirin, Heparin, antiplatelet drugs, or contrast
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Intracoronary imaging-Guided Drug-coated balloon strategy
DCB diameter and length will be determined based on Intracoronary imaging measurements, with additional lesion preparation performed at the operator's discretion according to the predefined intravascular imaging optimization criteria. |
In the intracoronary imaging-guided group, lesion preparation will be guided by intravascular imaging findings, with additional balloon dilatation or specialized devices used as needed. Following lesion preparation and DCB treatment, repeat Intracoronary imaging will be performed to assess lumen gain, residual stenosis, dissection morphology, and elastic recoil. The acceptable minimum lumen area (MLA) is ≥ 4.2 mm², with a target optimization criterion of MLA ≥ 70% of the mean reference lumen area. Patients meeting both the intracoronary imaging criteria and angiographic safety criteria will proceed to DCB treatment. If these criteria are not achieved but angiographic safety criteria are satisfied and the patient remains clinically stable, further optimization may be considered. If angiographic safety criteria remain unmet after observation, bailout drug-eluting stent (DES) implantation will be performed. |
|
Actieve vergelijker: CAG-guided Drug-coated balloon strategy
In the CAG-guided group, DCB treatment will be guided by conventional coronary angiography, with DCB diameter and length determined by visual angiographic assessment. |
For patients randomized to the CAG-guided group, the selection of lesion preparation devices, DCB sizing, and the need for bailout stenting will be determined by the operators based on coronary angiographic findings and clinical judgment. Patients meeting the predefined angiographic safety criteria after lesion preparation will proceed to DCB treatment. Bailout drug-eluting stent (DES) implantation will be performed if angiographic safety criteria are not met. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Target vessel failure
Tijdsspanne: 12 months
|
Incidence of a composite of cardiac death, target-vessel myocardial infarction and clinically indicated target vessel revascularization |
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Device success
Tijdsspanne: 0 day (during index PCI)
|
|
0 day (during index PCI)
|
|
Procedure success
Tijdsspanne: 7 days
|
Device success Freedom from in-hospital TVF |
7 days
|
|
Periprocedural complications
Tijdsspanne: 48 hours
|
Incidence of a composite of cardiac death, periprocedural myocardial infarction, acute target lesion/vessel thrombosis, and acute target lesion/vessel occlusion |
48 hours
|
|
Incidence of cardiac death
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
Incidence of cardiac death |
1, 12, 24, 36, and 60 months
|
|
Incidence of target-vessel myocardial infarction
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
Incidence of target-vessel myocardial infarction |
1, 12, 24, 36, and 60 months
|
|
Incidence of clinically indicated target vessel revascularization
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
Incidence of clinically indicated target vessel revascularization |
1, 12, 24, 36, and 60 months
|
|
Patient-oriented composite endpoint (PoCE)
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
Incidence of a composite of all-cause mortality, any myocardial infarction, any stroke, and any revascularization |
1, 12, 24, 36, and 60 months
|
|
all-cause mortality
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
all-cause mortality |
1, 12, 24, 36, and 60 months
|
|
Any myocardial infarction
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
Any myocardial infarction |
1, 12, 24, 36, and 60 months
|
|
Any stroke
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
Any stroke |
1, 12, 24, 36, and 60 months
|
|
Any revascularization
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
Any revascularization |
1, 12, 24, 36, and 60 months
|
|
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding)
Tijdsspanne: 1,12, 24, 36, and 60 months
|
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding (Bleeding type 3 or 5 according to the Bleeding ARC)) |
1,12, 24, 36, and 60 months
|
|
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)
Tijdsspanne: 1, 12, 24, 36, and 60 months
|
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5) |
1, 12, 24, 36, and 60 months
|
|
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR
Tijdsspanne: 1, 12, 24, 36 and 60 months
|
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR |
1, 12, 24, 36 and 60 months
|
|
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events
Tijdsspanne: 1, 12, 24, 36 and 60 months
|
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events |
1, 12, 24, 36 and 60 months
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- FW-ZEL-003
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Deidentified individual participant data that underlie the results reported in the primary publication will be made available to qualified researchers upon reasonable request and approval of a methodologically sound research proposal, subject to an appropriate data use agreement.
IPD-tijdsbestek voor delen
Beginning 36 months after publication of the primary study results and continuing for 5 years.
IPD-toegangscriteria voor delen
Deidentified individual participant data underlying the results reported in the primary publication will be available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators and, where applicable, relevant institutional or ethics authorities. Proposals that substantially overlap with prespecified ongoing analyses may be deferred until completion of those analyses. Data will be provided for the purposes specified in the approved proposal, subject to an appropriate data use agreement and applicable privacy and data protection requirements.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .